Mesalazina Eg (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the intestinal lining, decreasing the production of prostaglandins and leukotrienes. This local anti‑inflammatory effect reduces neutrophil activation and cytokine release, leading to less mucosal inflammation and promotion of healing in the colon.

The dosage of Mesalazina Eg is individualized by the prescribing clinician based on disease severity, location, and patient response. The prescriber determines the appropriate amount, frequency, and duration of therapy in accordance with clinical guidelines and patient needs.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Mesalazina Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesalazina Eg belongs to the aminosalicylate class, which provides topical anti‑inflammatory action directly in the colon. Compared with systemic steroids or immunomodulators, it generally has a more favorable safety profile but may be less potent for severe disease, making it suitable for mild to moderate ulcerative colitis and proctitis.

Store Mesalazina Eg at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Mesalazina Eg is a rectal formulation intended for local application. It is typically inserted into the rectum using the supplied applicator or enema device, following the instructions provided by the healthcare professional to ensure proper distribution of the medication.

Serious risks include severe allergic reactions such as anaphylaxis, significant gastrointestinal bleeding, hepatitis or marked liver enzyme elevation, pancreatitis, and rare events like toxic megacolon. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, blood in stool, or severe abdominal pain.

Mesalazina Eg should be avoided in patients with known hypersensitivity to mesalazine or other aminosalicylates. Caution is also advised for individuals with severe renal or hepatic impairment, and it is contraindicated in those with active severe infections or a history of hypersensitivity reactions to similar compounds.